 BrainStorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader KOL webinar on its Alzheimers Disease AD program today at 8:15 AM Eastern Time. The Company recently announced that it is expanding its clinical pipeline to develop NurOwn and begin a Phase 2 study in AD. 